Oudemansiella raphanipies Polysaccharides Improve Lipid Metabolism Disorders in Murine High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease

Nutrients. 2022 Oct 1;14(19):4092. doi: 10.3390/nu14194092.

Abstract

Oudemansiella raphanipies, also called "Edible Queen," is a mushroom that possesses antioxidant, anti-inflammatory, anti-bacterial, anti-tumor and immunity-enhancing properties. The present study aimed to assess the effect of O. raphanipies-derived polysaccharide (ORPS) on the progression of nonalcoholic fatty liver disease (NAFLD) in mice. We studied the structure of ORPS-1 by high-performance gel permeation chromatography (HPGPC), ion chromatography-mass spectrometry (GC-MS), and Fourier transform-infrared spectroscopy (FT-IR). ORPS-1 mainly comprised galactose, fucose, glucose, mannose, and xylose, following an 18:6:6:4:1 molar ratio. In addition, the therapeutic effect as well as a potential mechanism of ORPS-1 in the treatment of high-fat diet (HFD)-induced NAFLD were investigated. The results showed that ORPS-1 improved liver function, ameliorated liver steatosis, and reduced lipid droplet accumulation in HFD mice. A metabolomics approach with GC-MS was utilized to evaluate liver improvement by ORPS-1 treatment. Principal component analysis showed that liver metabolic profiling was significantly altered by HFD feeding or treatment with an intermediate dose of ORPS-1 in mice compared with that of control mice. By investigating the metabolic pathways with identified biomarkers, various pathways such as steroid biosynthesis, valine, leucine, and isoleucine biosynthesis, glycerol phospholipid metabolism, glyceride metabolism, and arginine and proline metabolism in HFD mice were observed to be significantly influenced by ORPS-1 treatment. The results indicate ORPS-1 metabolic effects on liver tissues, provide methods for assessing the molecular impact of ORPS-1 on NAFLD, and suggest the potential mechanism underlying its health benefits.

Keywords: Oudemansiella raphanipies; metabonomics; non-alcoholic fatty liver disease; polysaccharides.

MeSH terms

  • Agaricales* / metabolism
  • Animals
  • Antioxidants / pharmacology
  • Arginine / pharmacology
  • Biomarkers / metabolism
  • Diet, High-Fat / adverse effects
  • Fucose / pharmacology
  • Galactose / adverse effects
  • Glucose / metabolism
  • Glycerides / pharmacology
  • Glycerol / metabolism
  • Isoleucine / pharmacology
  • Leucine / pharmacology
  • Lipid Metabolism
  • Lipid Metabolism Disorders* / metabolism
  • Liver / metabolism
  • Mannose
  • Mice
  • Mice, Inbred C57BL
  • Non-alcoholic Fatty Liver Disease* / drug therapy
  • Non-alcoholic Fatty Liver Disease* / etiology
  • Non-alcoholic Fatty Liver Disease* / metabolism
  • Phospholipids / metabolism
  • Polysaccharides / metabolism
  • Proline / metabolism
  • Spectroscopy, Fourier Transform Infrared
  • Steroids / metabolism
  • Valine / pharmacology
  • Xylose / metabolism

Substances

  • Antioxidants
  • Biomarkers
  • Glycerides
  • Phospholipids
  • Polysaccharides
  • Steroids
  • Isoleucine
  • Fucose
  • Arginine
  • Proline
  • Xylose
  • Leucine
  • Valine
  • Glucose
  • Glycerol
  • Mannose
  • Galactose